Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparison of Third OAHA Add-on to Sitagliptin+Metformin in T2DM
NCT01709305Phase 4Completed
- Sponsor
- Merck & Co.
- Start
- Nov 2012
- Primary completion
- Apr 2015
- Modality
- Small Molecules
01
Overview
A Phase 4 trial of acarbose, repaglinide, gliclazide in type 2 diabetes mellitus (T2DM), sponsored by Merck & Co.. Started Nov 2012; status: completed.
02
Drugs
acarboserepaglinidegliclazide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01709305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01709305.